Skip to main content
. Author manuscript; available in PMC: 2018 May 8.
Published in final edited form as: Am J Transplant. 2016 Jul 13;17(1):81–90. doi: 10.1111/ajt.13910

Figure 4.

Figure 4

The survival of tolerant BALB/c allografts in Listeria-infected C57BL/6 recipients is not affected by anti-CD25 treatment. (A) Enriched percentage of Foxp3+ of CD4+ T cells in the tolerant allograft, compared to blood (Bld) and spleen (Spl) in tolerant mice and syngeneic (Syn) grafts at ≥ 60 days post-transplantation. (B) Percentage of Foxp3+ of CD4+ T cells in the tolerant allografts, prior to (D0) and 7, 14 and ≥30 days post-Listeria infection. Each symbol represents a single animal (N=≥7/group), data are presented as mean ± standard error, and statistical significance at p≤ *0.05, **0.01, ***0.001 and ****0.0005. Detailed gating strategy for graft infiltrating CD4+FoxP3+ and CD8+ cells is illustrated in Figure S1. (C) Uninfected (N=6) or day 14 post-infection recipients (N=11) with non-rejected hearts were treated with a single i.v. dose of anti-CD25 (PC61; 400 µg/mouse).